Monoclonal antibody · Agonist of CD137 (TNFRSF9) · developed by Compass Therapeutics
CTX-471 is a fully human IgG4 agonistic monoclonal antibody that binds and activates CD137 on T lymphocytes and natural killer cells. It enhances CD137-mediated signaling and promotes T-cell-mediated anti-tumor immune responses. The drug is being studied in glioblastoma, non-small cell lung cancer, small cell lung cancer, mesothelioma, melanoma, and head and neck cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07392957 | Phase 1/2 | Glioblastoma | Recruiting | CMPS |
| NCT03881488 | Phase 1 | Locally Advanced Solid Tumor | Completed | IQV |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
GlioblastomaHead and Neck CancerLocally Advanced Solid TumorMelanomaMesotheliomaMetastatic CancerNon-small Cell Lung CancerSmall Cell Lung Cancer
Updated Oct 3, 2026. Something wrong or missing? Report it on the CMPS page.
See CMPS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CMPS catalysts and pipeline →